SANDOZ GROUP N overview

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva ® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and quality Sandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolio Basel, April 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines,...

MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m 2 means Kundl can now manufacture 240 million packages per year Represents capacity increase of 20% over 2023 and more than doubling from 2021 output levels Automation and innovative technologies allow production of one billion more penicillin tablets and doubling of output for key pediatric...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales 1 of USD 2.5 billion, up 10% in constant currencies (up 11% in USD) Full-year 2023 net sales of USD 9.6 billion , up 7% in constant currencies (up 6% in USD) Strong growth across all three regions and double-digit growth in biosimilars both in the fourth quarter and full year Full-year 2023 core EBITDA margin of 18.1% , with strong contribution from net sales...

MEDIA RELEASE Wyost ® (denosumab-bddz) and Jubbonti ® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ® * (denosumab) and Prolia ® * (denosumab) FDA approval based on robust clinical studies and totality of evidence, which show no clinically meaningful differences from reference medicines Basel, March 5, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting Remco Steenbergen appointed as Sandoz CFO and member of Executive Committee as of July 1, 2024, and consequently not standing for re-election to Board of Directors Colin Bond to retire as CFO of Sandoz on June 30, 2024 Basel, March 5, 2024 - The Board of Directors of Sandoz...

MEDIA RELEASE CIMERLI ® *, a ranibizumab biosimilar, is interchangeable with LUCENTIS ® ** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for providers and patients Basel, March 4, 2024 – Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI ® * (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of anticipated...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual General Meeting François-Xavier Roger announced to pursue a new executive responsibility and therefore to step down from the Sandoz Board of Directors post publication of the financial statements 2023 Basel, February 1, 2024 - The Board of Directors of Sandoz announced today that it proposes Graeme...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko ® approved for all indications of reference medicine Tyruko ® biosimilar to treat adults with highly active relapsing remitting multiple sclerosis (RRMS) Launch strengthens well-established Sandoz biosimilar portfolio in Europe Basel, January 31, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Tyruko ® (natalizumab) in Germany from February 1....